Roth Capital Partners, a relationship-driven investment bank headquartered in Newport Beach, California, will host its 5th Annual Healthcare Opportunities Conference on September 29, 2026, at the Metropolitan Club in New York City. The invitation-only event will bring together C-suite executives from more than 30 public healthcare companies and leading institutional investors, according to an announcement from InvestorWire.
The conference will feature one-on-one and small-group meetings with companies representing biotechnology, life science tools and diagnostics, and medical technology. Discussions will cover critical topics including neuroscience, drug pricing and coverage, regulatory uncertainty and capital constraints in biotechnology, and minimal residual disease (MRD) monitoring in solid tumors. The event will be hosted by ROTH senior healthcare research analysts Jonathan Aschoff, Ph.D., Max Masucci, Boobalan Pachaiyappan, Ph.D., and Adam Walsh, MD.
Since 2010, ROTH has been involved in more than 600 transactions for healthcare clients representing more than $25 billion in total transaction value. This track record underscores the firm's deep expertise in the healthcare sector and its ability to connect growth companies with the investors who can fuel their expansion. The conference provides a vital platform for these companies to showcase their innovations and for investors to gain insights into emerging opportunities and challenges.
The event's focus on regulatory uncertainty and capital constraints is particularly timely, as biotechnology firms navigate an evolving landscape of drug pricing reforms and funding pressures. By facilitating direct dialogue between executives and investors, the conference may help shape investment strategies and foster partnerships that drive medical innovation. For the healthcare industry, such gatherings are essential for aligning capital with breakthrough therapies and diagnostics, ultimately impacting patient care and outcomes.
ROTH's full-service platform spans capital raising, high-impact equity research, macroeconomics, sales and trading, technical insights, derivatives strategies, M&A advisory, and corporate access. The firm's involvement in over 600 healthcare transactions since 2010 highlights its role as a key player in the sector. For more information on Roth, please visit www.roth.com.
The conference is part of ROTH's broader efforts to serve growth companies and their investors. A full calendar of events is available at https://ibn.fm/vDTjP.
InvestorWire, a specialized communications platform under the Dynamic Brand Portfolio at IBN, provides wire-grade press release syndication and related services. The platform offers editorial syndication to 5,000+ outlets and social media distribution to millions of followers. For full terms of use, see the disclaimer.
